Simultaneous tissue factor expression and phosphatidylserine exposure account for the highly procoagulant pattern of melanoma cell lines

Melanoma Research

Volumn 19, Issue 5, 2009, Pages 301-308

  Kirszberg, Clarice ^a,b   Lima, Luize G ^a   Da Silva De Oliveira, Andreia ^a   Pickering, William ^b   Gray, Elaine ^b   Barrowcliffe, Trevor W ^b   Rumjanek, Vivian M ^a   Monteiro, Robson Q ^a  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b NATIONAL INSTITUTE FOR BIOLOGICAL STANDARDS AND CONTROL   (United Kingdom)

Author keywords

Blood clotting; Melanoma; Phosphatidylserine; Thrombin; Tissue factor procoagulant

Indexed keywords

APROTININ; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 5A; BLOOD CLOTTING FACTOR 8A; BLOOD CLOTTING FACTOR 9A; PHOSPHATIDYLSERINE; PROCOAGULANT; PROTHROMBIN; THROMBIN; THROMBOPLASTIN;

ANIMAL CELL; ARTICLE; BLOOD CLOTTING; CANCER CELL CULTURE; CONTROLLED STUDY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANIMALS; BLOOD COAGULATION; CELL LINE, TUMOR; FLOW CYTOMETRY; HUMANS; MELANOMA; MELANOMA, EXPERIMENTAL; MICE; PHOSPHATIDYLSERINES; THROMBIN; THROMBOPLASTIN;

EID: 73349113512     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/CMR.0b013e32832e40fe     Document Type: Article

References (44)

1. Rickles FR, Edwards RL. Activation of blood coagulation in cancer: Trousseau's syndrome revisited. Blood 1983; 62:14-31.
2. Varki A. Trousseau's syndrome: multiple definitions and multiple mechanisms. Blood 2007; 110:1723-1729.
3. Donati MB. Cancer and thrombosis: from phlegmasia alba dolens to transgenic mice. Thromb Haemost 1995; 74:278-281.
4. Lip GY, Chin BS, Blann AD. Cancer and the prothrombotic state. Lancet Oncol 2002; 3:27-34.
5. Sørensen HT, Johnsen SP, Nørgård B, Zacharski LR, Baron JA. Cancer and venous thromboembolism: a multidisciplinary approach. Clin Lab 2003; 49:615-623.
6. White RH, Chew H,Wun T. Targeting patients for anticoagulant prophylaxis trials in patients with cancer: who is at highest risk? Thromb Res 2007; 120 (Suppl 2):S29-S40.
7. Rickles FR, Falanga A. Molecular basis for the relationship between thrombosis and cancer. Thromb Res 2001; 102:V215-V224.
8. Gomez K, McVey JH. Tissue factor initiated blood coagulation. Front Biosci 2006; 11:1349-1359.
9. Lentz BR. Exposure of platelet membrane phosphatidylserine regulates blood coagulation. Prog Lipid Res 2003; 42:423-438.
10. Connor J, Bucana C, Fidler IJ, Schroit AJ. Differentiation-dependent expression of phosphatidylserine in mammalian plasma membranes: quantitative assessment of outer-leaflet lipid by prothrombinase complex formation. Proc Natl Acad Sci U S A 1989; 86:3184-3188.
11. Barrowcliffe TW, Fábregas P, Jardi M, Cancelas J, Rabaneda M, Felez J. Procoagulant activity of T lymphoblastoid cells due to exposure of negatively charged phospholipid. Thromb Haemost 2002; 87:442-449.
12. Pickering W, Gray E, Goodall AH, Ran S, Thorpe PE, Barrowcliffe TW. Characterization of the cell-surface procoagulant activity of T-lymphoblastoid cell lines. J Thromb Haemost 2004; 2:459-467.
13. Chen J, Bierhaus A, Schiekofer S, Andrassy M, Chen B, Stern DM, Nawroth PP. Tissue factor-a receptor involved in the control of cellular properties, including angiogenesis. Thromb Haemost 2001; 86:334-345.
14. Rak J, Milsom C, May L, Klement P, Yu J. Tissue factor in cancer and angiogenesis: the molecular link between genetic tumor progression, tumor neovascularization, and cancer coagulopathy. Semin Thromb Hemost 2006; 32:54-70.
15. Rao LV, Pendurthi UR. Tissue factor-factor VIIa signaling. Arterioscler Thromb Vasc Biol 2005; 25:47-56.
16. Belting M, Ahamed J, Ruf W. Signaling of the tissue factor coagulation pathway in angiogenesis and cancer. Arterioscler Thromb Vasc Biol 2005; 25:1545-1550.
17. Markovic SN, Erickson LA, Rao RD,Weenig RH, Pockaj BA, Bardia A, et al. Malignant melanoma in the 21st century, part 1: epidemiology, risk factors, screening, prevention, and diagnosis. Mayo Clin Proc 2007; 82:364-380.
18. Markovic SN, Erickson LA, Rao RD,Weenig RH, Pockaj BA, Bardia A, et al. Malignant melanoma in the 21st century, part 2: staging, prognosis, and treatment. Mayo Clin Proc 2007; 82:490-513.
19. Mueller BM, Reisfeld RA, Edgington TS, Ruf W. Expression of tissue factor by melanoma cells promotes efficient hematogenous metastasis. Proc Natl Acad Sci U S A 1992; 89:11832-11836.
20. Bromberg ME, Konigsberg WH, Madison JF, Pawashe A, Garen A. Tissue factor promotes melanoma metastasis by a pathway independent of blood coagulation. Proc Natl Acad Sci U S A 1995; 92:8205-8209.
21. Im JH, Fu W,Wang H, Bhatia SK, Hammer DA, Kowalska MA, et al. Coagulation facilitates tumor cell spreading in the pulmonary vasculature during early metastatic colony formation. Cancer Res 2004; 64:8613-8619.
22. Ornstein DL, Zacharski LR. Treatment of cancer with anticoagulants: rationale in the treatment of melanoma. Int J Hematol 2001; 73:157-161.
23. Bennett DC, Cooper PJ, Hart IR. A line of non-tumorigenic mouse melanocytes, syngeneic with the B16 melanoma and requiring a tumour promoter for growth. Int J Cancer 1987; 39:414-418.
24. Geaquinto DL, Fernandes RS, Lima LG, Barja-Fidalgo C, Monteiro RQ. Procoagulant properties of human MV3 melanoma cells. Braz J Med Biol Res 2008; 41:99-105.
25. Petersen LC, Nørby PL, Branner S, Sørensen BB, Elm T, Stennicke HR, et al. Characterization of recombinant murine factor VIIa and recombinant murine tissue factor: a human-murine species compatibility study. Thromb Res 2005; 116:75-85.
26. Kirszberg C, Rumjanek VM, Monteiro RQ. Assembly and regulation of prothrombinase complex on B16F10 melanoma cells. Thromb Res 2005; 115:123-129.
27. Abe K, Shoji M, Chen J, Bierhaus A, Danave I, Micko C, et al. Regulation of vascular endothelial growth factor production and angiogenesis by the cytoplasmic tail of tissue factor. Proc Natl Acad Sci U S A 1999; 96:8663-8668.
28. Yu JL, May L, Lhotak V, Shahrzad S, Shirasawa S,Weitz JI, et al. Oncogenic events regulate tissue factor expression in colorectal cancer cells: implications for tumor progression and angiogenesis. Blood 2005; 105:1734-1741.
29. Palumbo JS, Talmage KE, Massari JV, La Jeunesse CM, Flick MJ, Kombrinck KW, et al. Tumor cell-associated tissue factor and circulating hemostatic factors cooperate to increase metastatic potential through natural killer cell-dependent and-independent mechanisms. Blood 2007; 110:133-141.
30. Nierodzik ML, Karpatkin S. Thrombin induces tumor growth, metastasis, and angiogenesis: evidence for a thrombin-regulated dormant tumor phenotype. Cancer Cell 2006; 10:355-362.
31. Fernandes RS, Kirszberg C, Rumjanek VM, Monteiro RQ. On the molecular mechanisms for the highly procoagulant pattern of C6 glioma cells. J Thromb Haemost 2006; 4:1546-1552.
32. Dvorak HF, Senger DR, Dvorak AM. Fibrin as a component of the tumor stroma: origins and biological significance. Cancer Metastasis Rev 1983; 2:41-73.
33. Wojtukiewicz MZ, Zacharski LR, Memoli VA, Kisiel W, Kudryk BJ, Rousseau SM, Stump DC. Malignant melanoma. Interaction with coagulation and fibrinolysis pathways in situ. Am J Clin Pathol 1990; 93:516-521.
34. Zacharski LR, Dunwiddie C, Nutt EM, Hunt J, Memoli VA. Cellular localization of activated factor X by Xa-specific probes. Thromb Haemost 1991; 65:545-548.
35. Zacharski LR, Memoli VA, Morain WD, Schlaeppi JM, Rousseau SM. Cellular localization of enzymatically active thrombin in intact human tissues by hirudin binding. Thromb Haemost 1995; 73:793-797.
36. Tellez C, Bar-Eli M. Role and regulation of the thrombin receptor (PAR-1) in human melanoma. Oncogene 2003; 22:3130-3137.
37. Depasquale I, Thompson WD. Prognosis in human melanoma: PAR-1 expression is superior to other coagulation components and VEGF. Histopathology 2008; 52:500-509.
38. Wojtukiewicz MZ, Kozlowski L, Ostrowska K, Dmitruk A, Zacharski LR. Low molecular weight heparin treatment for malignant melanoma: a pilot clinical trial. Thromb Haemost 2003; 89:405-407.
39. Sampsel JW, Macivor M, Barbera-Guillem E. Cure of metastatic melanoma with surgery, low-dose methotrexate and heparin: a case report. Melanoma Res 2004; 14:425.
40. LindemannW, Richter S, Schilling MK. Hirudin-based anticoagulant strategy during isolated limb perfusion in a patient with heparin-induced thrombocytopenia. Melanoma Res 2005; 15:287-290.
41. Donnelly KM, Bromberg ME, Milstone A, Madison-McNiff JM, Terwilliger G, Konigsberg WH, Cappello M. Ancylostoma caninum anticoagulant peptide blocks metastasis in vivo and inhibits factor Xa binding to melanoma cells in vitro. Thromb Haemost 1998; 79:1041-1047.
42. Esumi N, Fan D, Fidler IJ. I Inhibition of murine melanoma experimental metastasis by recombinant desulfatohirudin, a highly specific thrombin inhibitor. Cancer Res 1991; 51:4549-4556.
43. Zingali RB, Bianconi ML, Monteiro RQ. Interaction of bothrojaracin with prothrombin. Haemostasis 2001; 31:273-278.
44. Nazareth RA, Tomaz LS, Ortiz-Costa S, Atella GC, Ribeiro JM, Francischetti IM, Monteiro RQ. Antithrombotic properties of Ixolaris, a potent inhibitor of the extrinsic pathway of the coagulation cascade. Thromb Haemost 2006; 96:7-13.